RBR-7chtrj
Recruiting
未知
Augmenting pharmacological treatment of treatment-resistant social anxiety disorder with cognitive therapy
Instituto de Psiquiatria da UFRJ - IPUB0 sitesSeptember 13, 2017
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Instituto de Psiquiatria da UFRJ - IPUB
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A current principal diagnosis of social anxiety disorder by DSM\-5 criteria; A history of at least one unsuccessful adequate pharmacological treatment trials, operationalized as lack of response Clinical Global Impression\-improvement scale (CGI\-I) greater than or equal to 3, to at least 10 weeks of (i) SSRIs or venlafaxine at adequate dosage; with or without (ii) benzodiazepines (e.g. clonazepam 2 mg/day); A total score on the Liebowitz Social Anxiety Scale (LSAS) of 50 or greater; Man and woman with age of at least 18 years.
Exclusion Criteria
- •Pregnancy, lactation, and women of childbearing potential without accepted forms of contraception; Psychotic disorders, bipolar disorder, mental retardation, a recent history of alcohol or substance abuse or dependence; Severe organic medical disorder; Concurrent use of other psychotropic medications than detailed in inclusion criteria; Current or recent significant suicidality; Any concurrent psychotherapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Pharmaceutical-pharmacological interventions to improve drug therapy safety of inpatient carelow adherence, problems with drug application/use, patients' concerns regarding their drug therapyDRKS00026088Abteilung Klinische Pharmakologie und Pharmakoepidemiologie, Medizinische Klinik100
Completed
Phase 2
Effect of add-on medication (with dose increase, combined with anti-leukotriene , combined with steroid nasal spray)for allergic rhinitis patients who are not effective of normal dose of Bepotastine besilate .allergic rhinitisJPRN-UMIN000011336Graduate Scool of Medicine150
Completed
Not Applicable
Providing therapy with dose administration aids and existing cardiovascular medicines - PilotCardiovascular diseaseMedication adherenceCardiovascular - Other cardiovascular diseasesPublic Health - Other public healthACTRN12620001239954The George Institute for Global Health100
Active, not recruiting
Phase 1
Pharmacologic treatment augmentation in chronic depressionrandomized, controlled, double blinded, phase II studyMales and females between 18-64 years with a diagnosis ofchronic depressionMedDRA version: 21.1Level: LLTClassification code 10066555Term: Chronic depressionSystem Organ Class: 100000004873Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2019-001692-37-DEniversity Hospital Tuebingen60
Recruiting
Phase 1
Pharmacologic treatment augmentation in chronic depressionrandomized, controlled, double blinded, phase II study”Diagnosis of chronic depressionMedDRA version: 21.1Level: LLTClassification code: 10066555Term: Chronic depression Class: 10037175Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]CTIS2024-512478-86-00niversitaetsklinikum Tuebingen AöR60